Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-MAD immunochemotherapy for newly diagnosed primary central nervous system lymphoma
ChiCTR-IIR-16009117Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: complete remission rate. Planned start Oct 2016; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR-IIR-16009117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16009117.